CourageAS (pronounced ‘courageous’) Biotherapeutics is a biotech company established by Couragene and the Foundation for Angelman Syndrome Therapeutics (FAST). At CourageAS, we share a common vision: to transform lives of individuals with rare diseases through innovative genome editing therapies. Our joint venture brings together cutting-edge science and technology, and an unwavering commitment to potentially make a difference in the lives of those impacted by Angelman syndrome.

We believe that courage lies not only in scientific breakthroughs but also in our determination to create a better future for patients and their families.